Center for Orphan Drug Research
The focus of CODR research is rare pediatric neurological disorders.Since its inception in 2005, the Center for Orphan Drug Research (CODR) has been improving the care of individuals suffering from rare diseases through research, increased education efforts, and by taking an active role in shaping public policy applicable to rare diseases and orphan drug development.
Rare Disease Day 2017
Research brings hope to people living with a rare disease and their familiesThis event is free and open to the public
Friday, February 24, 2017
11 AM - 1 PM
University of Minnesota McNamara Alumni Center
* Lunch provided
The theme of the 10th International Rare Disease Day is research. We are pleased to present a unique opportunity that con-nects Minnesota researchers with Minnesota Patient Advocacy Groups. Read more
While some bear names you’ve likely never heard of, other examples may surprise you. Huntington’s disease, Tourette’s syndrome and muscular dystrophy are all classified as rare diseases. In all, more than 7,000 medical disorders are considered rare.
For decades, Americans diagnosed with rare diseases had little hope. Drugs used to treat such conditions – known as “orphan drugs” – often never made it out of the lab as prioritization was put on drugs that would help conditions affecting millions. Then, in 1983, Congress passed the Orphan Drug Act in order to stimulate the development of new treatments for rare diseases. The move worked; since 1983 more than 350 new drugs have been developed.
Today, the University of Minnesota Center for Orphan Drug Research is investing new resources into the development of orphan drugs and drug delivery systems that could impact the lives of millions of people both in Minnesota and across the United States.